2024-10-19 08:47:28
Innovent Announces Phase 1 Clinical Data of IBI322 (CD47/PD-L1 Bispecific Antibody) in the Treatment of Anti-PD-(L)1-resistant Classic Hodgkin Lymphoma Patients at the EHA 2023 Annual Meeting
Corporate/ 2023-07-24
Innovent Announces Phase 1 Clinical Data...

ROCKVILLE,Md. and SUZHOU,China,June 12,2023-- Innovent Biologics,Inc. ("Innovent") (HKEX: 01801),a world-class biopharmaceutical c...

HKSH Medical Group and UCLA Health signed a Development Agreement
Health/ 2023-07-22
HKSH Medical Group and UCLA Health signe...

Strengthen Partnership for Knowledge Transfer in Cancer Management HONG KONG,June 12,2023-- HKSH Medical Group (HKSH) and UCLA Health have s...

CUSMail

CusMail provide the Latest News , Business and Technology News Release service. Most of our news is paid for distribution to meet global marketing needs. We can provide you with global market support.

© CUSMAIL. All Rights Reserved. Operate by Paid Release